Equecabtagene autoleucel vs Idecabtagene vicleucel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Equecabtagene autoleucel
Marketed by IASO Biotherapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT06464991 (registry estimate)
No aligned efficacy figure on record for this race.
Idecabtagene vicleucel
Marketed by Bristol-Myers Squibb
NCT03651128 · Phase 3 · completed
Randomized, open-label Phase 3 trial (n=386) demonstrating significant improvement in PFS vs standard regimens in relapsed/refractory multiple myeloma (NEJM 2023).
Next expected readout: May 2027 · NCT05393804 (registry estimate)
Reported efficacy
Progression-free survival (PFS): PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001) (met)
Result source: NCT03651128
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Equecabtagene autoleucel | Idecabtagene vicleucel |
|---|---|---|
| PFS, median | —Trial running · NCT06464991 | 8.9bNCT03361748 |
| OS, median | —Trial running · NCT06464991 | 28.3bNCT03361748 |
| ORR | —Trial running · NCT06464991 | 74.5%bNCT03361748 |
| VGPR or better | —Trial running · NCT06464991 | —Not posted · NCT03651128 |
| MRD negativity | —Trial running · NCT06464991 | —Not posted · NCT03651128 |
PFS, median
- Equecabtagene autoleucel
- —Trial running · NCT06464991
- Idecabtagene vicleucel
- 8.9bNCT03361748
OS, median
- Equecabtagene autoleucel
- —Trial running · NCT06464991
- Idecabtagene vicleucel
- 28.3bNCT03361748
ORR
- Equecabtagene autoleucel
- —Trial running · NCT06464991
- Idecabtagene vicleucel
- 74.5%bNCT03361748
VGPR or better
- Equecabtagene autoleucel
- —Trial running · NCT06464991
- Idecabtagene vicleucel
- —Not posted · NCT03651128
MRD negativity
- Equecabtagene autoleucel
- —Trial running · NCT06464991
- Idecabtagene vicleucel
- —Not posted · NCT03651128
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Equecabtagene autoleucel: no structured comparison results are available for Multiple Myeloma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Equecabtagene autoleucel: 0 of 4 rows · Idecabtagene vicleucel: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Idecabtagene vicleucel |
|---|---|
| Dropout rate | 73.7%a NCT03361748 · Phase 2 show 1 more result5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT03361748 · Phase 2 show 1 more result— NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 78.8%a NCT03361748 · Phase 2 show 1 more result22.5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | show 1 more resultlymphocyte count decreased 85% neutrophil count decreased 77.5% white blood cell decreased 72.5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Idecabtagene vicleucel
show 7 more results
show 7 more results
show 7 more results
show 7 more results
+ 7 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Equecabtagene autoleucel's landscape · Idecabtagene vicleucel's landscape